EGF inhibits constitutive internalization and palmitoylation-dependent degradation of membrane-spanning procancer CDCP1 promoting its availability on the cell surface

Oncogene

Volumn 34, Issue 11, 2015, Pages 1375-1383

  Adams, M N ^a   Harrington, B S ^a   He, Y ^a   Davies, C M ^a   Wallace, S J ^a   Chetty, N P ^a   Crandon, A J ^a   Oliveira, N B ^a   Shannon, C M ^a   Coward, J I ^a   Lumley, J W ^b   Perrin, L C ^a   Armes, J E ^a   Hooper, J D ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b WESLEY HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CDCP1 PROTEIN, HUMAN; CELL ADHESION MOLECULE; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; IL6 PROTEIN, HUMAN; INTERLEUKIN 6; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR PROTEIN;

ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER TRANSPLANTATION; CELL MEMBRANE; CELL MOTION; ENZYME ACTIVATION; FEMALE; HUMAN; IMMUNOLOGY; LIPOYLATION; METABOLISM; MOUSE; NONOBESE DIABETIC MOUSE; OVARY TUMOR; PATHOLOGY; PROTEIN TRANSPORT; SCID MOUSE; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CELL MEMBRANE; CELL MOVEMENT; ENZYME ACTIVATION; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; INTERLEUKIN-6; LIPOYLATION; MEMBRANE PROTEINS; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; PROTEIN TRANSPORT; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSPLANTATION, HETEROLOGOUS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84896689206     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.88     Document Type: Article

References (37)

1. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. New Engl J Med 2008; 358: 1160-1174.
2. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 2013; 13: 714-726.
3. Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors - impact on future treatment strategies. Nat Rev Clin Oncol 2010; 7: 493-507.
4. He Y, Wortmann A, Burke LJ, Reid JC, Adams MN, Abdul-Jabbar I et al. Proteolysisinduced N-terminal ectodomain shedding of the integral membrane glycoprotein CUB domain-containing protein 1 (CDCP1) is accompanied by tyrosine phosphorylation of its C-terminal domain and recruitment of Src and PKC ä. J Biol Chem 2010; 285: 26162-26173.
5. Uekita T, Sakai R. Roles of CUB domain-containing protein 1 signaling in cancer invasion and metastasis. Cancer Sci 2011; 102: 1943-1948.
6. Wortmann A, He Y, Deryugina EI, Quigley JP, Hooper JD. The cell surface glycoprotein CDCP1 in cancer - insights, opportunities, and challenges. IUBMB Life 2009; 61: 723-730.
7. Hooper JD, Zijlstra A, Aimes RT, Liang H, Claassen GF, Tarin D et al. Subtractive immunization using highly metastatic human tumor cells identifies SIMA135/CDCP1, a 135 kDa cell surface phosphorylated glycoprotein antigen. Oncogene 2003; 22: 1783-1794.
8. Awakura Y, Nakamura E, Takahashi T, Kotani H, Mikami Y, Kadowaki T et al. Microarray-based identification of CUB-domain containing protein 1 as a potential prognostic marker in conventional renal cell carcinoma. J Cancer Res Clin Oncol 2008; 134: 1363-1369.
9. Emerling BM, Benes CH, Poulogiannis G, Bell EL, Courtney K, Liu H et al. Identification of CDCP1 as a hypoxia-inducible factor 2alpha (HIF-2alpha) target gene that is associated with survival in clear cell renal cell carcinoma patients. Proc Natl Acad Sci USA 2013; 110: 3483-3488.
10. Razorenova OV, Finger EC, Colavitti R, Chernikova SB, Boiko AD, Chan CK et al. VHL loss in renal cell carcinoma leads to up-regulation of CUB domain-containing protein 1 to stimulate PKCaδ-driven migration. Proc Natl Acad Sci USA 2011; 108: 1931-1936.
11. Miyazawa Y, Uekita T, Hiraoka N, Fujii S, Kosuge T, Kanai Y et al. CUB domaincontaining protein 1, a prognostic factor for human pancreatic cancers, promotes cell migration and extracellular matrix degradation. Cancer Res 2010; 70: 5136-5146.
12. Ikeda J, Oda T, Inoue M, Uekita T, Sakai R, Okumura M et al. Expression of CUB domain containing protein (CDCP1) is correlated with prognosis and survival of patients with adenocarcinoma of lung. Cancer Sci 2009; 100: 429-433.
13. Gao W, Chen L, Ma Z, Du Z, Zhao Z, Hu Z et al. Isolation and phenotypic characterization of colorectal cancer stem cells with organ-specific metastatic potential. Gastroenterology 2013; 145: 636-646, e5.
14. Uekita T, Jia L, Narisawa-Saito M, Yokota J, Kiyono T, Sakai R. CUB domain-containing protein 1 is a novel regulator of anoikis resistance in lung adenocarcinoma. Mol Cell Biol 2007; 27: 7649-7660.
15. Liu H, Ong SE, Badu-Nkansah K, Schindler J, White FM, Hynes RO. CUB-domain-containing protein 1 (CDCP1) activates Src to promote melanoma metastasis. Proc Natl Acad Sci USA 2011; 108: 1379-1384.
16. Uekita T, Tanaka M, Takigahira M, Miyazawa Y, Nakanishi Y, Kanai Y et al. CUB-domain-containing protein 1 regulates peritoneal dissemination of gastric scirrhous carcinoma. Am J Pathol 2008; 172: 1729-1739.
17. Deryugina EI, Conn EM, Wortmann A, Partridge JJ, Kupriyanova TA, Ardi VC et al. Functional role of cell surface CUB domain-containing protein 1 in tumor cell dissemination. Mol Cancer Res 2009; 7: 1197-1211.
18. Casar B, He Y, Iconomou M, Hooper JD, Quigley JP, Deryugina EI. Blocking of CDCP1 cleavage in vivo prevents Akt-dependent survival and inhibits metastatic colonization through PARP1-mediated apoptosis of cancer cells. Oncogene 2012; 31: 3924-3938.
19. Casar B, Rimann I, Kato H, Shattil SJ, Quigley JP, Deryugina EI. In vivo cleaved CDCP1 promotes early tumor dissemination via complexing with activated beta1 integrin and induction of FAK/PI3K/Akt motility signaling. Oncogene 2013; 33: 255-268.
20. Fukuchi K, Steiniger SC, Deryugina E, Liu Y, Lowery CA, Gloeckner C et al. Inhibition of tumor metastasis: functional immune modulation of the CUB domain containing protein 1. Mol Pharm 2010; 7: 245-253.
21. Kollmorgen G, Niederfellner G, Lifke A, Spohn GJ, Rieder N, Vega Harring S et al. Antibody mediated CDCP1 degradation as mode of action for cancer targeted therapy. Mol Oncol 2013; 7: 1142-1151.
22. Siva AC, Wild MA, Kirkland RE, Nolan MJ, Lin B, Maruyama T et al. Targeting CUB domain-containing protein 1 with a monoclonal antibody inhibits metastasis in a prostate cancer model. Cancer Res 2008; 68: 3759-3766.
23. Dong Y, He Y, de Boer L, Stack MS, Lumley JW, Clements JA et al. The cell surface glycoprotein CUB domain-containing protein 1 (CDCP1) contributes to epidermal growth factor receptor-mediated cell migration. J Biol Chem 2012; 287: 9792-9803.
24. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-137.
25. Kulbe H, Chakravarty P, Leinster DA, Charles KA, Kwong J, Thompson RG et al. A dynamic in flammatory cytokine network in the human ovarian cancer micro-environment. Cancer Res 2012; 72: 66-75.
26. Blaskovic S, Blanc M, van der Goot FG. What does S-palmitoylation do to membrane proteins? FEBS J 2013; 280: 2766-2774.
27. Adams MN, Christensen ME, He Y, Waterhouse NJ, Hooper JD. The role of palmitoylation in signalling, cellular trafficking and plasma membrane localization of protease-activated receptor-2. PLoS One 2011; 6: e28018.
28. Adams MN, Pagel CN, Mackie EJ, Hooper JD. Evaluation of antibodies directed against human protease-activated receptor-2. Naunyn Schmiedebergs Arch Pharmacol 2012; 385: 861-873.
29. Dietzen DJ, Hastings WR, Lublin DM. Caveolin is palmitoylated on multiple cysteine residues. Palmitoylation is not necessary for localization of caveolin to caveolae. J Biol Chem 1995; 270: 6838-6842.
30. Joffre C, Barrow R, Menard L, Calleja V, Hart IR, Kermorgant S. A direct role for Met endocytosis in tumorigenesis. Nat Cell Biol 2011; 13: 827-837.
31. Miyazawa Y, Uekita T, Ito Y, Seiki M, Yamaguchi H, Sakai R. CDCP1 regulates the function of MT1-MMP and invadopodia-mediated invasion of cancer cells. Mol Cancer Res 2013; 11: 628-637.
32. Benes CH, Wu N, Elia AE, Dharia T, Cantley LC, Soltoff SP. The C2 domain of PKCδ is a phosphotyrosine binding domain. Cell 2005; 121: 271-280.
33. Sandilands E, Frame MC. Endosomal trafficking of Src tyrosine kinase. Trends Cell Biol 2008; 18: 322-329.
34. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239-246.
35. Macdonald JL, Pike LJ. A simplified method for the preparation of detergent-free lipid rafts. J Lipid Res 2005; 46: 1061-1067.
36. Morris DP, Lei B, Wu YX, Michelotti GA, Schwinn DA. The alpha1a-adrenergic receptor occupies membrane rafts with its G protein effectors but internalizes via clathrin-coated pits. J Biol Chem 2008; 283: 2973-2985.
37. Wortmann A, He Y, Christensen ME, Linn M, Lumley JW, Pollock PM et al. Cellular settings mediating Src Substrate switching between focal adhesion kinase tyrosine 861 and CUB-domain-containing protein 1 (CDCP1) tyrosine 734. J Biol Chem 2011; 286: 42303-42315.